. Successful prevention and intervention efforts aimed at reducing cannabis use, misuse and related outcomes require a better understanding of why some people use cannabis whereas others do not. Lifetime cannabis use, defined as any use of cannabis during lifetime, is a heritable trait: a meta-analysis of twin studies 4 estimated the heritability to be approximately 45%. Twin studies have shown there is substantial overlap in the genetic factors influencing cannabis use and those underlying problematic cannabis use (abuse or dependence) 5, 6 . Several GWASs have tried to identify genetic variants underlying cannabis use phenotypes [7] [8] [9] [10] [11] . Recently, Demontis et al. 11 performed the largest GWAS for cannabis use disorder to date, with a discovery sample of 2,387 cases and almost 50,000 controls, plus a replication sample of 5,501 cases and ~300,000 controls. They found one genome-wide significant risk locus for cannabis use disorder, a single nucleotide polymorphism (SNP) that is a strong marker for CHRNA2 expression. Their follow-up analyses showed that cannabis-dependent individuals had a decreased expression of this gene in the cerebellum, as well as in other brain regions.
The largest GWAS of lifetime cannabis use to date is from the International Cannabis Consortium (ICC) and is based on a sample size of 32,330 individuals in the discovery sample along with 5,627 individuals in the replication sample 10 . Although no individual SNPs reached genome-wide significance, gene-based tests identified four genes significantly associated with lifetime cannabis use: NCAM1, CADM2, SCOC and KCNT2. Notably, NCAM1 has previously been linked to other substance use phenotypes (for example, refs. 12, 13 ), and following publication of the study, CADM2 was found to be associated with alcohol consumption 14 , personality 15 , reproductive success and risk-taking behavior 16 in other GWASs. These results indicate that CADM2 may play a role in a broader personality profile of sensation-seeking and risk-taking behavior in general.
Here we present a GWAS of lifetime cannabis use on a substantially larger sample, providing more power to identify genetic variants.
As mentioned above, cannabis use has been linked to a variety of mental health outcomes, including substance abuse and dependence and psychiatric disorders 3 . In particular, the relationship between cannabis use and schizophrenia has been the subject of intensive research and debate. It has long been established that the prevalence of cannabis use is higher in patients with schizophrenia 17, 18 . A substantial body of evidence supports the hypothesis that cannabis use increases the risk for developing psychoses and schizophrenia 19 , but other hypotheses (namely, schizophrenia increases the use of cannabis, or the association is due to (genetic) pleiotropy) have also been posed. Previous studies have shown that genetic risk factors for cannabis use and schizophrenia are positively correlated 20, 21 . However, a genetic correlation does not provide insight in the direction of causation. With Mendelian randomization it is possible to examine the causality of the association between cannabis use and schizophrenia, and recently it has become possible to apply this method using summary statistics from GWASs 22 . Previous Mendelian randomization studies have investigated the link between lifetime cannabis use and schizophrenia risk, but findings were inconsistent. Vaucher et al. 23 tested for causal effects from cannabis use to schizophrenia and found evidence for a causal influence of cannabis use on schizophrenia risk. Gage et al. 24 tested bidirectional effects and found weak evidence for a causal effect of cannabis use on schizophrenia risk and much stronger evidence for a causal effect in the other direction. The results from our GWAS provide more power to examine the causal association between cannabis use and liability to schizophrenia.
Here we report the largest GWAS yet for lifetime cannabis use. We increased the sample size substantially by meta-analyzing GWAS results from the ICC study (N = 35,297), along with new data from the UK Biobank (N = 126,785) and 23andMe (N = 22,683). The combined sample size of this study was N = 184,765, five times as large as the previous largest GWAS on lifetime cannabis use. We tested the association of millions of SNPs with lifetime cannabis use and estimated the heritability of lifetime cannabis use based on all SNPs. Tests of association for individual genetic variants were complemented with gene-based tests of association and S-PrediXcan analysis. The latter was used to identify genes with differential expression levels in cannabis users versus nonusers. We further estimated the genetic correlation of lifetime cannabis use with other traits, including use of other substances and mental health traits, such as schizophrenia. Lastly, we performed bidirectional two-sample Mendelian randomization analysis to examine whether there was evidence for a causal relationship from cannabis use to schizophrenia risk, and from liability to schizophrenia to cannabis use.
Results
Genome-wide association meta-analysis. The meta-analysis resulted in eight independent genome-wide significant SNP associations (linkage disequilibrium (LD) R 2 < 0.1, window size 250 kb) on chromosomes 3, 7, 8, 11, 16 and 17 ( Fig. 1 , Table 1 and  Supplementary Table 1 ). The top SNP and two other independent associations were located in CADM2 on chromosome 3 (rs2875907, P = 9.38 × 10 -17
; rs1448602, P = 6.55 × 10 -11
; rs7651996, P = 2.37 × 10 -9 ). Other hits were located in ZNF704, SDK1, NCAM1, RABEP2 or ATP2A1 and SMG6 (Fig. 2) . All SNPs combined explained 11% (h SNP 2 = 0.11, s.e. = 0.01) of the individual differences in lifetime cannabis use. Supplementary Figs. 1-3 and Supplementary Table 2 provide information on results of the individual GWASs (ICC, UK Biobank and 23andme).
Gene-based test of association and expression. Gene-based tests of associations in MAGMA 25 identified 35 genes genome-wide significantly associated with lifetime cannabis use (Fig. 3, Table 2 , Supplementary Fig. 4 and Supplementary Table 3 ). These genes were located in 5 regions that were already identified in the SNP-based analysis (including those containing CADM2 and NCAM1) and in 11 other regions ( Supplementary Fig. 5 ).
S-PrediXcan analysis 26 revealed 133 Bonferroni-corrected significant associations across tissues targeting 21 unique genes  (Supplementary Tables 4 and 5 ). Eight genes were also significant in the gene-based test, whereas 13 were newly identified. For genes identified in multiple tissues, directions of effects were largely consistent across tissues (Supplementary Fig. 6 ). Again, the most significant finding was CADM2; genetic variants associated with increased liability to use cannabis are predicted to upregulate expression levels of CADM2 in eight nonbrain tissues, including whole blood (z = 5.88, P = 4.17 × 10 -9 ). Of note, although CADM2 is expressed more widely in brain than in other tissues ( Supplementary  Fig. 7) , the top SNP, rs2875907, regulates the expression of CADM2 only in nonbrain tissues ( Supplementary Fig. 8 ). Exploration of S-PrediXcan results in UK Biobank data (https://imlab.shinyapps. io/gene2pheno_ukb_neale/) showed that CADM2 expression is significantly associated with multiple traits, including increased risk-taking, body mass index and reduced feelings of anxiety. Like the SNP-and gene-based tests of association, the S-PrediXcan analysis detected a strong signal in a high-LD region at 16p11.2. Supplementary Table 3 provides an overview of all genes that were identified in the gene-based test of association and the S-PrediXcan analyses, along with information about the gene product and previously identified associations with the gene.
Genetic correlations with other traits. Using our GWAS results and those of other GWASs, we estimated the genetic correlation of lifetime cannabis use with 25 traits of interest, including substance use, personality and mental health phenotypes. Fourteen traits were significantly genetically correlated with lifetime cannabis use after correction for multiple testing (Fig. 4 and Supplementary Table 6 ). Positive genetic correlations were found with substance use phenotypes, including smoking and alcohol use and dependence, as well as with mental health phenotypes, including ADHD and schizophrenia. Furthermore, positive genetic correlations were found with risk-taking behavior, openness to experience, and educational attainment, as well as a negative correlation with conscientiousness.
Causal association between liability to schizophrenia and cannabis use: two-sample Mendelian randomization. A positive genetic correlation was found between genetic risk factors for cannabis use and schizophrenia (r g = 0.25, s.e. = 0.3, P < 0.001). To examine whether there was evidence for a causal effect of cannabis use on schizophrenia risk and vice versa, we performed bidirectional twosample Mendelian randomization analysis 22 . In our main analysis, inverse-variance-weighted (IVW) regression analysis, we found some weak (nonsignificant) evidence for a causal influence of lifetime cannabis use on schizophrenia risk, but only for the genetic instrument containing SNPs associated with cannabis use under the P-value threshold 1 × 10 -5
. The IVW regression odds ratio was 1.10 (95% confidence interval (CI) 0.99-1.21, P = 0.074). We found stronger evidence for a causal positive influence of schizophrenia risk on lifetime cannabis use, the IVW regression odds ratio being 1.16 (95% CI 1.06-1.27, P = 0.001; see Table 3, Supplementary  Figs. 9 and 10, and Supplementary Tables 7-9) .
To determine the robustness of these findings, we performed four sensitivity analyses that rely on distinct assumptions regarding instrument validity. The sensitivity analyses showed a consistent pattern supporting weak evidence for a causal effect of cannabis use on schizophrenia risk and strong evidence for a causal effect of liability to schizophrenia on cannabis use (Table 3) . As an exception, the evidence provided by MR-Egger SIMEX (Mendelian randomization Egger simulation extrapolation) for a causal relation from liability to schizophrenia risk to cannabis use was very weak. However, since the Egger intercept was not significantly different from 0 (Supplementary Table 10 ), indicating no pleiotropic effects for the SNPs included in the genetic instruments 27 , it is likely that this method simply lacked power to be able to reject the null hypothesis of no causal effect 28 .
Discussion
SNP-and gene-based tests revealed several SNPs and genes strongly associated with lifetime cannabis use. Overall, 11% of the variation in the phenotype was explained by the combined effect of SNPs, which amounts to approximately 25% of twin-based heritability estimates 4 . CADM2 and NCAM1, both identified in the original ICC meta-analysis 10 , were among the strongest findings in the SNP-based and gene-based tests. The CADM2 gene (cell adhesion molecule 2) is a synaptic cell adhesion molecule and is part of the immunoglobulin superfamily. Notably, CADM2 has previously been identified in GWASs of other behavioral phenotypes, including alcohol consumption 14 , processing speed 29 , and number of offspring and risk-taking behavior 16 . A large-scale phenome-wide scan showed that . The statistical test comprised linear regression; significance was tested two-sided. 
+++
Independent hits were defined as R 2 < 0.01, window size 250 kb. The threshold was set at P < 5 × 10 -8 (conventional genome-wide significant threshold; significance was tested two-sided). CADM2 was associated with various personality traits, with the risk variant being associated with reduced anxiety, neuroticism and conscientiousness and with increased risk-taking 15 . Taken together, these findings suggest that risk variants in CADM2 are associated with a broad profile of a risk-taking, optimistic and care-free personality 15 . Cannabis use has previously been associated with related personality traits, including high levels of impulsivity and novelty seeking 30, 31 . NCAM1 (neural cell adhesion molecule 1) also encodes a cell adhesion protein and is member of the immunoglobulin superfamily. The encoded protein is involved in cell-matrix interactions and cell differentiation during development 32 . NCAM1 is located in the NCAM1-TTC12-ANKK1-DRD2 gene cluster, which is related to neurogenesis and dopaminergic neurotransmission. This gene cluster has been associated with smoking, alcohol use and illicit drug use 12,33-35 and has been implicated in psychiatric disorders, such as schizophrenia and mood disorders 36, 37 .
A putatively novel finding comprises the 16p11.2 region (identified in the SNP and gene-based tests of association and in S-PrediXcan analysis). Deletions and duplications in this region have previously been reported to be associated with autism and schizophrenia 38, 39 , while a common 16p11.2 inversion underlies susceptibility to asthma and obesity 40 . The inversion explains a substantial proportion of variability in expression of multiple genes in this region, including TUFM and SH2B1 40 . Given the high LD in this region and high levels of coexpression of the differentially expressed genes, follow-up studies will be needed to determine which genes are functionally driving the association with cannabis use.
Several of the top genes from the gene-based and/or S-PrediXcan analyses have previously shown an association with other traits, including schizophrenia (for example, TUFM, NCAM1), body mass index or obesity (for example, SH2B1, APOBR, ATXN2L), , Bonferroni corrected threshold of P < 0.05 adjusted for 18,293 tests); underlined in green are the genes that were identified in the S-PrediXcan analysis only (P < 1.92 × 10 alcohol use (for example, ALDH2), intelligence and cognitive performance (CNNM2, CCDC101) and externalizing and impulsive phenotypes (for example, CADM2; see Supplementary Table 3) . Also of note is the association with HTR1A; this gene has been implicated in alcohol and nicotine codependence 41 , body mass index 42 , psychiatric disorders 43, 44 and antipsychotic pharmacological treatment response 45 . At the phenotypic level, associations between cannabis use and psychiatric disorders 2 and use of other substances 30 are well established.
There are two previous studies that found significant SNP associations for a cannabis use phenotype. Sherva et al. 46 found three SNPs significantly associated with cannabis dependence. In our results only one of the SNPs was available (rs77378271) and was not significantly associated with lifetime cannabis use (P = 0.144). The other two SNPs (rs143244591 and rs146091982) or their high-LD proxies were not available in our data. The SNPs rs77378271 and rs146091982 were located in genes CSDM1 and SLC35G1, respectively, and neither of those were significant in our gene-based results (P = 0.96 and P = 0.49, respectively). Demontis et al. 11 found one independent significant signal on chromosome 8 to be associated with cannabis dependence (with top SNP rs56372821, a strong expression quantitative trait locus (eQTL) for CHRNA2). Neither the SNP (P = 0.55) nor the gene (P = 0.52) was significantly associated with lifetime cannabis use in our study. The protein encoded by CHRNA2 is a subunit of certain nicotinic acetylcholine receptors, and Demontis et al. 11 offer three potential biological explanations for the link between cannabis intake and CHRNA2. However, it is possible that while CHRNA2 is associated with cannabis dependence, it does not act in the initial stages of cannabis use, which are more related to personality and risk-taking behaviors and less to the actual effects of cannabis intake on the brain.
The genetic correlation analyses revealed genetic overlap of cannabis use with a broad range of traits, including positive associations with substance use and mental health phenotypes. Furthermore, positive genetic correlations were found with risk-taking behavior, openness to experience, and educational attainment, as well as a negative correlation with conscientiousness. The range of correlations suggests that genetic liability to lifetime cannabis use should be viewed in a broader context of personality and mental health traits. Specifically, the substantial genetic correlations with risktaking behavior and openness to experience may indicate that liability to start using cannabis is an indication of one's personality. The positive genetic correlation between lifetime cannabis use and educational attainment was unexpected and in contrast to a previous study that found a negative genetic correlation between cannabis dependence and educational attainment 11 . We therefore investigated phenotypic associations of cannabis use with household income and fluid intelligence using UK Biobank data. Within Caucasian participants of UK Biobank (N = 438,870), categorically rated household income was higher among lifetime cannabis users compared to nonusers (χ 2 (4) = 2,243, P = 2.2 × 10 -16 ). Cannabis users also scored higher on fluid intelligence (t(50,856) = 25.13, P < 2 × 10 -16 ). These findings are in agreement with observations by Patrick et al. 47 , who showed that cannabis use is associated with higher childhood family social economic status in a survey of US families. Possibly, environments more often experienced by those with backgrounds of higher social economic status, such as universities, increase accessibility to cannabis, explaining how a positive For the gene-based test, the P-value was set at P < 2.74 × 10 -6 , Bonferroni corrected threshold of P < 0.05 adjusted for 18,293 tests. For the S-PrediXcan analysis, P < 1.92 × 10 -7 , Bonferroni corrected threshold of P < 0.05 adjusted for 259,825 tests. The MAGMA statistical test is based on multiple regression. Significance was tested two-sided in both analyses. Genes that were significant in both analyses are bolded; the others were significant in the S-PrediXcan analysis alone. correlation between lifetime cannabis use and educational attainment in our study could arise. We also found a significant genetic correlation between cannabis use and schizophrenia (r g = 0.25), which is in line with previous findings 20, 21 , indicating that genetic risk factors for cannabis use and schizophrenia are positively correlated. As for the causal direction of this correlation, we found weak evidence for a causal link from cannabis use to schizophrenia risk and much stronger evidence for a causal link from liability to schizophrenia to cannabis use. This suggests that individuals with a higher liability to schizophrenia have a higher risk to start using cannabis. These results are in contrast with results from a Mendelian randomization study by Vaucher et al. 23 , who found strong evidence for a causal effect from cannabis use to schizophrenia risk (causality in the other direction was not tested).
However, our findings are in line with a Mendelian randomization study by Gage et al. 24 , who used genetic instruments similar to ours and also found weak evidence for a causal effect of cannabis use to schizophrenia risk and much stronger evidence for a causal effect in the other direction. Our findings may indicate that individuals at risk for developing schizophrenia experience prodromal symptoms or negative affect that make them more likely to start using cannabis to cope or self-medicate 48 . The lack of strong evidence of a causal influence of cannabis use on schizophrenia risk may be due to the lower power of the instrumental variables. The instrumental variable based on schizophrenia SNPs explained 3.38% of variance in liability to schizophrenia. For cannabis use, the genetic instruments explained 1.12% and 0.15% of the variance in cannabis use for SNPs included with P < 1 × 10 -5 and P < 5 × 10 -8
, respectively. The results of our study should be interpreted in view of its strength and limitations. Important strengths of this study include the analyses of the largest population sample to date, which has led to a substantial increase in power to identify genetic variants associated with lifetime cannabis use. The association analyses were complemented with several follow-up analyses to further investigate the genetic basis of cannabis use and the extent to which the genetic etiology of cannabis use overlaps with that of other complex phenotypes. Strong genetic correlations across a wide spectrum of traits are observed, confirming that lifetime cannabis use is a relevant measure of an individual's vulnerability.
Our study also has several limitations. First, lifetime cannabis use was analyzed as a dichotomous measure combining experimental and regular users in a single group. Additionally, the different samples varied substantially regarding the age of the participants, the prevalence of cannabis use, and the country's policies regarding cannabis use. All these factors may introduce heterogeneity that may reduce the power to detect genetic associations. Second, power of some analyses may have been limited. For example, the Mendelian randomization analysis from cannabis to schizophrenia risk was based on an instrument of only five SNPs, and the summary statistics of some traits used for the genetic correlation analyses in LD-score regression (for example, cannabis dependence) were based on a small sample size. Finally, some regions identified in the SNP-based analyses did not appear in the gene-based analyses. In particular, inspection of the region around rs9773390 (in ZNF704) showed that the top SNP in this region was isolated and that the SNP was only available in two of the three datasets (not in UK Biobank). SNPs in LD with the top SNP that were included in all three datasets were not genome-wide significant. Thus, this result may not represent a robust association.
In summary, our GWAS of lifetime cannabis use, which is the largest to date, revealed significant SNP and gene associations in 16 Significant results (P < 0.05, tested two-sided) are shown in bold. IVW, inverse-variance-weighted regression analysis; MR-Egger SIMEX, Mendelian randomization Egger simulation extrapolation; GSMR, generalized summary-data-based Mendelian randomization (HEIDI outlier analysis detects and eliminates from the analysis instruments that show significant pleiotropic effects on both risk factor and disease); B, risk coefficient representing the change in outcome for a one-unit increase in the exposure variable; SE(B), standard error of the B coefficient; OR, odds ratios representing the odds of schizophrenia for lifetime cannabis users versus nonusers (when cannabis is the exposure) or the odds of lifetime cannabis use for those with a schizophrenia diagnosis versus those without (when schizophrenia is the exposure). 
Methods
Samples. Data from three sources were obtained: ICC, 23andMe and UK Biobank (total N = 184,765). We used existing GWAS summary statistics from the ICC, based on data from 35 Phenotype and covariates. For all participants, self-report data were available on whether the participant had ever used cannabis during their lifetime: yes (1) versus no (0). Measurement instruments and phrasing of the questions about lifetime cannabis use differed across the samples. For the ICC study this has been described for each cohort in the original paper 10 . As part of their online questionnaire, 23andMe used the following phrase to examine lifetime cannabis use: "Have you ever in your life used the following: Marijuana?" The UK Biobank, as part of an online follow-up questionnaire, asked: "Have you taken CANNABIS (marijuana, grass, hash, ganja, blow, draw, skunk, weed, spliff, dope), even if it was a long time ago?" Genotyping and imputation. Genotyping was performed on various genotyping platforms and standard quality control checks were performed before imputation. Genotype data were imputed using the 1000 Genomes phase 1 release reference set 49 for ICC and 23andMe, and the Haplotype Reference Consortium reference set 50 for the UK Biobank sample. Information about samples, genotyping, imputation and quality control is summarized in Supplementary Tables 11 and 12 . After quality control, the ICC sample comprised 35,297 individuals and 6,643,927 SNPs, the 23andMe sample 22,683 individuals and 7,837,888 SNPs, and the UK Biobank sample 126,785 individuals and 10,827,718 SNPs.
Statistics. All statistical tests were two-sided and, unless stated otherwise, we used the conventional P-value of 0.05 for significance testing. When necessary, Bonferroni correction for multiple testing was applied. Randomization and blinding procedures do not apply to our study design.
Genome-wide association analyses and meta-analysis.
We conducted the GWASs in 23andMe and UK Biobank samples separately. Associations between the binary phenotype and SNPs were tested using a logistic regression model accounting for the effects of sex, age, ancestry and genotype batch (and age 2 in the UK Biobank sample). The GWAS for UK Biobank was performed in PLINK 1.9 51 and the GWAS for 23andMe using an internally developed pipeline. We then meta-analyzed the GWAS results from ICC, 23andMe and UK Biobank. Prior to conducting the meta-analysis, additional quality control of the summary statistics of each study was conducted in EasyQC 52 . Because of varying GWAS methods and sample characteristics (Supplementary Table 11) , slightly different quality control criteria were used for the three samples (Supplementary Table 12 ). All three samples were aligned with the Haplotype Reference Consortium panel using the EasyQC R-package 52 , to ensure that rs-numbers and chromosome-basepair positions referred to the same variants and to correct for strand effects. Variants were deleted if they had a minor allele frequency (MAF) diverging more than 0.15 from that in the reference panel.
We applied genomic control to the three GWAS files before meta-analysis. Inflation due to stratification was estimated using LD-score regression, which can differentiate inflation due to population stratification from that due to real signal. The intercept was used to correct the standard errors (SEs) of the estimated effect sizes as follows:
The intercepts were b 0 = 1.005 (s.e.= 0.007) for ICC, b 0 = 1.004 (s.e. = 0.007) for 23andMe and b 0 = 1.022 (s.e. = 0.008) for UK Biobank. We then performed a fixed effects metaanalysis based on effect sizes (log odds ratios) and standard errors in METAL 53 . We applied the conventional P-value threshold of 5 × 10 -8 as an indication of genome-wide significance. The meta-analysis was performed on 11,733,371 SNPs that passed quality control. The combined sample size of the meta-analysis was 184,765 individuals, although the sample size varied per SNP due to differential missingness across samples.
Manhattan and Q-Q plots for the GWASs, meta-analysis and gene-based test results were created using the R-package qqman 54 . Regional plots were created using LocusZoom 55 , with varying window size for optimal visualization.
Gene-based test of association. Testing associations on the level of protein-coding genes can be more biologically meaningful and is more powerful (lower multiple testing burden) than testing solely on the level of SNPs. Gene-based analysis was used to test associations for the combined effect of SNPs in protein-coding genes taking into account LD between the SNPs and the size of the gene. The analysis was conducted in MAGMA (v 1.6) 25 , which uses the 1000 Genomes reference panel (Phase 3, 2012) to control for LD. SNPs were mapped to genes if they were located in or within 10 kb of the gene; 5,710,956 SNPs (49%) could be mapped to at least one of 18,293 protein-coding genes in the reference panel. The significance threshold was set at P < 2.74 × 10 -6 (Bonferroni corrected P-value for 18,293 tests).
Identification of genes with differential expression levels between cannabis users and nonusers. We used S-PrediXcan to integrate eQTL (expression quantitative trait loci) information with our GWAS summary statistics to identify genes whose genetically predicted expression levels are associated with cannabis use 26 . Briefly, S-PrediXcan estimates gene expression weights by training a linear prediction model in samples with both gene expression and SNP genotype data. The weights are then used to predict gene expression from GWAS summary statistics, while incorporating the variance and covariance of SNPs from an LD reference panel. We used expression weights for 48 tissues from the GTEx Project (V7) and the DGN whole blood cohort generated by Gamazon et al. 56 , and LD information from the 1000 Genomes Project Phase 3 57 . These data were processed with β values and standard errors from the lifetime cannabis use GWAS meta-analysis to estimate the expression-GWAS association statistic. We used a transcriptome-wide significance threshold of P < 1.92 × 10 -7 , which is the Bonferroni corrected threshold when adjusting for all tissues and genes (i.e., N = 259,825 gene-based tests in the GTEx and DGN reference sets).
We used the GTEx Portal (https://www.gtexportal.org/home/; GTEx Analysis Release V7) 58 to obtain gene expression levels of CADM2 across tissues. We used the same portal to plot a multi-tissue eQTL comparison of the top SNP, rs2875907. The multi-tissue eQTL plot shows both the single-tissue eQTL P-value and the multi-tissue posterior probability from METASOFT 59 .
SNP-based heritability analysis. The proportion of variance in liability to cannabis use that could be explained by the aggregated effect of the SNPs (h SNPs 2 ) was estimated using LD-score regression analysis 60 . The method is based on the premise that an estimated SNP effect size includes effects of all SNPs in LD with that SNP. A SNP that tags many other SNPs will have a higher probability of tagging a causal genetic variant compared to a SNP that tags few other SNPs. The LD score estimates the amount of genetic variation tagged by a SNP within a specific population. Accordingly, assuming a trait with a polygenic architecture, SNPs with a higher LD score have on average stronger effect sizes than SNPs with lower LD scores. When regressing the effect size from the association analysis against the LD score for each SNP, the slope of the regression line provides an estimate of the proportion of variance accounted for by all analyzed SNPs 60 . For this analysis, we included 1,179,898 SNPs that were present in all cohorts and the HapMap 3 reference panel. Standard LD scores were used as provided by Bulik-Sullivan et al. 60 based on the Hapmap 3 reference panel, restricted to European populations 61 .
Genetic correlations with other substances and mental health phenotypes. We used cross-trait LD-score regression 62 to estimate the genetic correlation between lifetime cannabis use and 25 other traits using GWAS summary statistics. The genetic covariance is estimated using the slope from the regression of the product of z-scores from two GWASs on the LD score. The estimate represents the genetic covariation between the two traits based on all polygenic effects captured by SNPs. Summary statistics from well-powered GWASs were available for 25 relevant substance use and mental health traits, including nicotine, alcohol and caffeine use, schizophrenia, depression, bipolar disorder and loneliness (Supplementary Table 6 ). To correct for multiple testing we adopted a Bonferroni corrected P-value threshold of significance of 0.002 (0.05/25). LD scores were based on the HapMap 3 reference panel, restricted to European populations.
Causal association between cannabis use and schizophrenia: two-sample Mendelian randomization. We performed two-sample Mendelian randomization analyses (MR) 22 to examine whether there was evidence for a causal relationship from cannabis use to schizophrenia and vice versa. Analyses were performed with the R package of database and analytical platform MR-Base 63 and with the gsmr R package, which implements the GSMR (generalized summary-data-based Mendelian randomization) method 64 . MR utilizes genetic variants strongly associated with an exposure variable as an 'instrument' to test for causal effects of the exposure on an outcome variable. This approach minimizes the risk of spurious findings due to confounding or reverse causation present in observational studies, provided that the following assumptions are met: (i) the genetic instrument is predictive of the exposure variable, (ii) the genetic instrument is independent of confounding effects, and (iii) the genetic instrument is not directly associated with the outcome variable, other than by its potential causal effect through the exposure (i.e., there is no directional pleiotropy) 65 . Two-sample MR refers to the application of MR methods to well-powered summary association results estimated in non-overlapping sets of individuals 22 in order to reduce instrument bias toward the exposure-outcome estimate.
Bidirectional causal effects were tested between lifetime cannabis use and schizophrenia. We used genetic variants from our cannabis GWAS, as well as those from the largest schizophrenia GWAS 66 , to serve as instruments (gene-exposure association). For lifetime cannabis use we used two genetic instruments: (i) an instrument including all independent genetic variants that were genome-wide significantly associated with lifetime cannabis use (P < 5 × 10 -8 ; 5 SNPs) and (ii) an instrument including independent variants with a more lenient significance threshold (P < 1 × 10 -5 ; 69 SNPs). For schizophrenia we used one genetic instrument, including independent genetic variants that were genome-wide significantly associated with schizophrenia (instrument P < 5 × 10 -8
; 109 SNPs). Information on the included SNPs in the genetic instruments is provided in Supplementary Table 7 .
Genetic variants were pruned (R 2 < 0.001) and the remaining genetic variants (or proxies (R 2 ≥ 0.8), when an instrumental SNP was not available in the other GWAS) were then identified in GWAS summary-level data of the outcome variable (gene-outcome association). Note that not all independent SNPs identified in the exposure dataset have been included in the analyses because not all exposure SNPs or their proxies were also available in the outcome dataset and because some SNPs were palindromic (see Supplementary Table 7) .
Evidence for both a gene-exposure and a gene-outcome association suggests a causal effect, provided that the MR assumptions are met. To combine estimates from individual genetic variants, we applied inverse-variance-weighted (IVW) linear regression 67 . In addition, four sensitivity analyses more robust to horizontal pleiotropy were applied, each relying on distinct assumptions regarding instrument validity: weighted median 68 , MR-Egger SIMEX 27 , weighted mode 69 and generalized summary-data-based Mendelian randomization (GSMR) 64 . These sensitivity analyses rely on orthogonal assumptions, making their inclusion important for triangulation. The weighted median approach provides a consistent estimate of the causal effect even when up to 50% of the weight comes from invalid instruments 68 . MR-Egger regression applies Egger's test to MR instruments that consist of multiple genetic variants 27, 28 . MR-Egger provides a consistent estimate of the causal effect, provided that the strength of the genetic instrument (the association between SNPs and exposure) does not correlate with the effect the instrument has on the outcome (i.e., the InSIDE assumption: instrument strength independent of direct effect). This is a weaker assumption than the assumption of no pleiotropy. MR-Egger may, however, be biased when the NOME (no measurement error) assumption is violated-i.e., the assumption that the SNP-exposure associations are known rather than estimated. Violation of NOME can be quantified with the I 2 statistic, which ranges between 0 and 1. A value below 0.9 indicates a considerable risk of bias. This bias can be corrected for with MR-Egger simulation extrapolation, SIMEX 70 . Since I 2 ranged between 0.7 and 0.9 for our analyses, we report results from MR-Egger SIMEX in Table 3 . The weighted mode methods can produce an unbiased result, as long as the most common causal effect estimate is a consistent estimate of the true causal effect: the zero modal pleiotropy assumption (ZEMPA) 69 . Finally, we performed GSMR, a method that leverages power from multiple genetic variants while accounting for LD between these variants 64 . Because GSMR accounts for LD, genetic variants that were included in GSMR instruments were pruned at a higher threshold of R 2 < 0.05 (instead of R 2 < 0.001 for the other MR analyses). Zhu et al. 64 showed that the gain of power from including SNPs in higher LD than 0.05 is limited. GSMR also allows extra filtering for SNPs that are suspected to have pleiotropic effects on both the exposure and the outcome (HEIDI filtering).
To calculate variance explained (R 2 ) by the instrument, first we selected a single SNP to obtain an estimate of the phenotypic variance, var(y). Assuming effect sizes are normally distributed, we used the quantile function of the Student t-distribution to transform the P-value of the SNP association into an estimate of t, t . The number of degrees of freedom and N were based on the effective sample size, + 4 / (1 / cases 1 / controls) . The effective sample sizes were estimated at N = 130,072 for schizophrenia and N = 180,934 for cannabis use. The corresponding value of r was calculated using the formula = − − t r R N / (1 )/ ( 2) 2 , and we obtained the R 2 that corresponds to t with the online tool http://vassarstats. net/rsig.html. Subsequently, we approximated the variance of the phenotype y using var(y) = [2 × MAF × (1 -MAF) × β 2 ]/R 2 , in which MAF denotes the minor allele frequency and β the effect size of the specific SNP. Finally, we used the estimated value of var(y) to calculate the R 2 for the remaining SNPs of interest
)/var(y) and summed the R 2 of all SNPs of interest included in the instrumental variable to obtain an estimate of the total R 
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A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Software and code
Policy information about availability of computer code
Data collection
For this study, we meta-analyzed genetic and phenotype data from 3 different cohorts. Data collection procedures differed per cohort and are summarized in the Methods section (for details on data collection in the ICC cohorts see . In general, DNA was extracted from blood or saliva samples, genotyped, and imputed using European reference data. Phenotype information was collected using paper-and-pencil or online surveys.
Data analysis PLINK 2.0-genomewide association tool; MAGMA v1.06-gene-based tests; S-PrediXcan -gene expression analysis; LD score regressiongenetic correlations and heritability; R qqman -visualisation of GWAS results; LocusZoom -creation of regional plots; GTEx Analysis Release V7 -eQTL; METASOFT -eQTL forest plot; MR-Base -mendelian randomization; R gsmr -mendelian randomization; METALmeta-analysis *all software mentioned here is publicly available For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. All studies must disclose on these points even when the disclosure is negative.
Sample size
A previous GWAS of the International Cannabis Consortium with a sample size of ~33,000 had limited power to detect genomewide significant hits. We expanded this sample with all available data that we had access to, resulting in a 5-fold increase in sample size, providing sufficient power to detect genomewide signals.
Data exclusions Extensive quality control procedures were used to select valid SNPs and individuals using pre-established criteria.
These have been described in Supplementary Table S12 and include exclusion of related individuals and individuals with missing data, variants with a low HWE, a low minor allele frequency, a low imputation quality score, or high missingness rates, and variants whose alleles and allele frequency differ from those in reference panels. For secondary analysis, sometimes a subset of the genome-wide data was used (i.e., SNPs that could be mapped to a gene in gene-based tests, SNPs that were present in reference files that were used by LocusZoom, LDscore regression, or S-PrediXcan).
